| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5859021 (Pediatric) | VIIV HLTHCARE | Antiviral combinations |
Nov, 2012
(11 years ago) | |
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
Combivir is owned by Viiv Hlthcare.
Combivir contains Lamivudine; Zidovudine.
Combivir has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Combivir are:
- US5859021*PED
- US5905082
- US5905082*PED
Combivir was authorised for market use on 26 September, 1997.
Combivir is available in tablet;oral dosage forms.
Combivir can be used as treatment of hiv.
The generics of Combivir are possible to be released after 18 November, 2016.
Drugs and Companies using LAMIVUDINE; ZIDOVUDINE ingredient
Market Authorisation Date: 26 September, 1997
Treatment: Treatment of hiv
Dosage: TABLET;ORAL
More Information on Dosage
COMBIVIR family patents
